Naveed Masani, MD
Nephrology · Mineola, NYNPI 1487618559
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Rockwell Medical, Inc. at 59.7% of the total. Reporting peaked in 2020 at $4,488 and has fallen 65.7% since, to $1,541 in 2024.
Across 19 payments — averaging $395.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rockwell Medical, Inc.$4K
- CSL Behring$2K
- Outset Medical Inc$1K
- Novo Nordisk$125
- Fresenius USA Marketing, Inc.$74
- Gilead$25
- plus $43 from 3 others
Across 599 payments — averaging $1181.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$186K
- Novo Nordisk AS$182K
- GSK$128K
- Abbott$85K
- CSL Behring$66K
- Hoffmann-la Roche Limited$57K
- plus $3K from 1 others
What the payments were for
- Consulting fees$4,48860%
- Travel & lodging$2,28830%
- Food & beverage$6849%
- Education$140%
- Entertainment$491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rockwell Medical, Inc. | 5 | $4,488 |
| CSL Behring | 5 | $1,516 |
| Outset Medical Inc | 3 | $1,252 |
| Novo Nordisk | 1 | $125 |
| Fresenius USA Marketing, Inc. | 1 | $74 |
| Gilead | 1 | $25 |
| Nxstage Medical, Inc. | 1 | $15 |
| Baxter Healthcare | 1 | $14 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRIFERIC$4,300
How this compares
$7,522 in reported general payments places this provider in the 85th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 112 | $125,290 |
| JardianceEmpagliflozin | 71 | $106,690 |
| Eplerenone | 261 | $39,527 |
| LokelmaSodium Zirconium Cyclosilicate | 41 | $33,806 |
| EliquisApixaban | 24 | $23,340 |
| JanuviaSitagliptin Phosphate | 11 | $12,482 |
| Cinacalcet Hcl | 39 | $11,984 |
| Febuxostat | 58 | $11,146 |
| Valsartan | 271 | $9,640 |
| VascepaIcosapent Ethyl | 15 | $8,981 |
| Tacrolimus | 21 | $8,840 |
| Mycophenolate Mofetil | 24 | $6,870 |
| Mycophenolic AcidMycophenolate Sodium | 11 | $5,384 |
| Torsemide | 260 | $5,146 |
| Colchicine | 68 | $4,930 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Mineola
- Steven FishbaneMineola$207K
- Binny KoshyMineola$170K
- Payam ShakouriPoughkeepsie$930K
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Bruce SpinowitzBronx$465K
- Steven CocaNew York$445K
- Joseph RoglieriTroy$425K
- Jai RadhakrishnanNew York$369K
- Savneek ChughHawthorne$325K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.